The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Array BioPharma; Asana Biosciences; Merck; Novartis; Replimune; Syndax; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)
Other Relationship - Boehringer Ingelheim
 
Emerson A. Lim
No Relationships to Disclose
 
Manish Sharma
Consulting or Advisory Role - Abbvie; Bayer; Eisai; Ipsen; Taiho Pharmaceutical
 
Dale Randall Shepard
Consulting or Advisory Role - Lilly; Sanofi
Speakers' Bureau - Celgene; Genentech/Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); GITR (Inst); Halozyme (Inst); Ignyta (Inst); Kinex (Inst); Pfizer (Inst); VBL Therapeutics (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Infinity Pharmaceuticals (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Gini F. Fleming
Honoraria - Curio Science
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - TTC Oncology
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule; Bayer
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Adam ElNaggar
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Clovis Oncology; Tesaro
Travel, Accommodations, Expenses - Caris Life Sciences
 
Adeboye H. Adewoye
Employment - Compugen
Leadership - Compugen
Stock and Other Ownership Interests - Compugen
Research Funding - Compugen
 
John Hunter
Employment - Compugen
Leadership - Compugen
Stock and Other Ownership Interests - Compugen
Research Funding - Compugen
Patents, Royalties, Other Intellectual Property - Compugen
 
Ecaterina Elena Ileana Dumbrava
No Relationships to Disclose
 
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Bristol-Myers Squibb; Compugen; Genentech/Roche; HUYA Bioscience International; Iovance Biotherapeutics; Janssen; Merck; Novartis; Regeneron
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Rgenix (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Biothera; Bristol-Myers Squibb; Compugen; Genentech/Roche; HUYA Bioscience International; Iovance Biotherapeutics; Janssen; Regeneron
 
Drew W. Rasco
Consulting or Advisory Role - Boehringer Ingelheim; Lilly
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Birdie (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Daniel A. Vaena
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Peloton Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence; Genomic Health